Feds to Biotech: No More Fibbing!
Feds to Biotech: No More Fibbing!
“A little-noted change in drug-approval procedures is a step toward avoiding more ImClone-style stock scandals “
Feds to Biotech: No More Fibbing!
“A little-noted change in drug-approval procedures is a step toward avoiding more ImClone-style stock scandals “
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.

Leave a Reply
Want to join the discussion?Feel free to contribute!